Viridian Therapeutics, Inc. (VRDN)
24.18
+0.16
(+0.67%)
USD |
NASDAQ |
Aug 25, 16:00
24.18
0.00 (0.00%)
After-Hours: 19:59
Viridian Therapeutics Profit Margin (Quarterly) : -44.76K% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -44.76K% |
| March 31, 2026 | -74.40K% |
| December 31, 2025 | -77.26K% |
| September 30, 2025 | -49.03% |
| June 30, 2025 | -134.3K% |
| March 31, 2025 | -120.7K% |
| December 31, 2024 | -89.79K% |
| September 30, 2024 | -89.17K% |
| June 30, 2024 | -90.27K% |
| March 31, 2024 | -67.42K% |
| December 31, 2023 | -92.86K% |
| September 30, 2023 | -66.19K% |
| June 30, 2023 | -76.48K% |
| March 31, 2023 | -69.54K% |
| December 31, 2022 | -43.60K% |
| September 30, 2022 | -2.42K% |
| June 30, 2022 | -11.52K% |
| March 31, 2022 | -11.89K% |
| December 31, 2021 | -13.53K% |
| September 30, 2021 | -6.75K% |
| June 30, 2021 | -1.65K% |
| March 31, 2021 | -1.27K% |
| December 31, 2020 | -168.0K% |
| September 30, 2020 | |
| June 30, 2020 | -3.83K% |
| Date | Value |
|---|---|
| March 31, 2020 | -971.5% |
| December 31, 2019 | -1.15K% |
| September 30, 2019 | -1.62K% |
| June 30, 2019 | -353.9% |
| March 31, 2019 | -3.13K% |
| December 31, 2018 | -2.17K% |
| September 30, 2018 | -954.6% |
| June 30, 2018 | -399.4% |
| March 31, 2018 | -97.43% |
| December 31, 2017 | -535.7% |
| September 30, 2017 | -357.7% |
| June 30, 2017 | -1.02K% |
| March 31, 2017 | -1.51K% |
| December 31, 2016 | -1.18K% |
| September 30, 2016 | -445.1% |
| June 30, 2016 | -286.8% |
| March 31, 2016 | -337.2% |
| December 31, 2015 | -452.2% |
| September 30, 2015 | -629.1% |
| June 30, 2015 | -349.0% |
| March 31, 2015 | -408.4% |
| December 31, 2014 | -345.0% |
| September 30, 2014 | -125.8% |
| June 30, 2014 | -258.2% |
| December 31, 2013 | -18.63% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 10.23% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Anika Therapeutics, Inc. | 10.15% |
| Savara, Inc. | -- |
| Vericel Corp. | 2.85% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -60.66% |
| Return on Assets | -46.72% |
| Return on Invested Capital | -53.73% |
| Gross Profit Margin (Quarterly) | 58.80% |
| Operating Margin (Quarterly) | -44.46K% |
| Return on Net Operating Assets | -1.87K% |